Abstract
During a clinical trial of duration of chemotherapy in small cell lung cancer (SCLC), 71 of 610 patients (11.6%) died in the first 3 weeks. Chemotherapy consisted of cyclophosphamide 1 g m-2 i.v. day 1, etoposide 100 mg t.d.s. orally days 1-3, vincristine 2 mg i.v. day 1. The time of death was found to be nonrandomly distributed within the first chemotherapy cycle, with a peak incidence between days 7 and 12 after chemotherapy. Patients were matched with controls who were the next cases entered into the study who did not die in the first 3 weeks. Patients dying early were more likely to have clinical hepatomegaly (P less than 0.0001), and ECOG score greater than or equal to 1 (P less than 0.00001). As a group these patients also had a higher alkaline phosphatase (P less than 0.0002), an elevated blood urea (P less than 0.00001) and a lower serum albumin (P less than 0.0001) than controls. It is probable that infection contributes to the death of these already ill patients at a time when the blood count is low. Early deaths have been noted in two other large trials using regimens including etoposide. Prophylactic antibiotics or dosage modification may prevent the early death of these high risk patients.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Feld R., Evans W. K., DeBoer G., Quirt I. C., Shepherd F. A., Yeoh J. L., Pringle J. F., Payne D. G., Herman J. G., Chamberlain D. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol. 1984 Apr;2(4):294–304. doi: 10.1200/JCO.1984.2.4.294. [DOI] [PubMed] [Google Scholar]
- Hirsch F. R., Hansen H. H., Hansen M., Osterlind K., Vindeløv L. L., Dombernowsky P., Sørensson S. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol. 1987 Apr;5(4):585–591. doi: 10.1200/JCO.1987.5.4.585. [DOI] [PubMed] [Google Scholar]
- Juma F. D. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol. 1984;26(5):591–593. doi: 10.1007/BF00543491. [DOI] [PubMed] [Google Scholar]
- Osterlind K., Sörenson S., Hansen H. H., Dombernowsky P., Hirsch F. R., Hansen M., Rørth M. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res. 1983 Dec;43(12 Pt 1):6085–6089. [PubMed] [Google Scholar]
- Pflüger K. H., Schmidt L., Merkel M., Jungclas H., Havemann K. Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. Cancer Chemother Pharmacol. 1987;20(1):59–66. doi: 10.1007/BF00252961. [DOI] [PubMed] [Google Scholar]
- Souhami R. L., Bradbury I., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 1985 Jun;45(6):2878–2882. [PubMed] [Google Scholar]
- Souhami R. L., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S., Mantell B. S., Fearon F., Bradbury I. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial. Br Med J (Clin Res Ed) 1984 Jun 2;288(6431):1643–1646. doi: 10.1136/bmj.288.6431.1643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Van den Berg H. W., Desai Z. R., Wilson R., Kennedy G., Bridges J. M., Shanks R. G. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol. 1982;8(2):215–219. doi: 10.1007/BF00255487. [DOI] [PubMed] [Google Scholar]